Management of stable COPD: An update

Current Respiratory Medicine Reviews

Volumn 9, Issue 6, 2013, Pages 352-359

  Corlateanu, Alexandru ^a,b   Montanari, Gloria ^c   Mathioudakis, Alexandros G ^d   Botnaru, Victor ^a,b   Siafakas, Nikolaos ^e  

^a STATE UNIVERSITY OF MEDICINE AND PHARMACY NICOLAE TESTEMITANU   (Moldova)

^b ERS National Delegate for Moldova GOLD National Leader for Moldova   (Moldova)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^e UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Chronic obstructive pulmonary disease (COPD); Disease management; Pharmacotherapy; Phenotypes; Rehabilitation

Indexed keywords

ACEBROPHYLLINE; ACLIDINIUM BROMIDE; BAMIFYLLINE; BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CARMOTEROL; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOXOFYLLINE; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; FORMOTEROL FUMARATE PLUS MOMETASONE FUROATE; GLYCOPYRRONIUM BROMIDE; INDACATEROL; INFLUENZA VACCINE; IPRATROPIUM BROMIDE; LONG ACTING DRUG; MACROLIDE; MUCOLYTIC AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; OLODATEROL; PNEUMOCOCCUS VACCINE; ROFLUMILAST; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG; VILANTEROL; XANTHINE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; EXERCISE TOLERANCE; FORCED EXPIRATORY VOLUME; HUMAN; LONG TERM CARE; LUNG FUNCTION; META ANALYSIS (TOPIC); MONOTHERAPY; NICOTINE REPLACEMENT THERAPY; OXYGEN THERAPY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY REHABILITATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING CESSATION; TREATMENT RESPONSE; VACCINATION;

EID: 84904727645     PISSN: 1573398X     EISSN: 18756387     Source Type: Journal    
DOI: 10.2174/1573398X10666140222001646     Document Type: Article

References (72)

1. Pauwels R, Buist AS, Calverley PA, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2001; 163: 1256-76.
2. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2014. Available from: http://www. goldcopd. org/. Accessed January 2014.
3. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. Available from: http://www. goldcopd. org/. Accessed January 2013.
4. O'Reilly J, Jones MM, Parnham J, et al. Management of stable chronic obstructive pulmonary disease in primary and secondary care: summary of updated NICE guidance. BMJ 2010; 340.
5. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011. Available from: http://www. goldcopd. org/. Accessed January 2012.
6. Celli BR, Cote CG, Marin JM, et al. The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index in Chronic Obstructive Pulmonary Disease. N Engl J Med 2004; 350: 1005-12.
7. Cote C, Dordelly L, Celli B. Impact of COPD Exacerbations on Patient-Centered Outcomes. CHEST 2007; 131: 696-704.
8. Celli B. Update on the Management of COPD. Chest 2008; 133: 1451-62.
9. Burgel PR, Paillasseur JL, Caillaud D, et al. Clinical COPD phenotypes: a novel approach using principal component and cluster analyses. Eur Respir J 2010; 36: 531-9.
10. Marsh SE, Travers J, Weatherall M, et al. Proportional classifications of COPD phenotypes. Thorax 2008; 63: 761-7.
11. Calverley PMA, Rabe KF, Goehring U-M, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. The Lancet 2009; 374: 685-94.
12. Fabbri LM, Calverley PMA, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. The Lancet 2009; 374: 695-703.
13. Calverley PMA, Rabe KF, Goehring U-M, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. The Lancet 2009; 374: 685-94.
14. Corlateanu A, Siafakas N, Botnaru V. Defining COPD: from simplistic approach to multilateral assessment of COPD. Curr Respir Care Reports 2012; 1: 177-82.
15. Miravitlles M, Calle M, Soler-Cataluña JJ. Clinical Phenotypes of COPD: Identification, Definition and Implications for Guidelines. Archivos de Bronconeumología (English Version) 2012; 48: 86-98.
16. Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Spanish COPD Guidelines (GesEPOC), Pharmacologic Treatment of Stable COPD. Archivos de Bronconeumología (English Version) 2012; 48: 247-57.
17. Anthonisen NR, Connett JE, Murray RP. Smoking and Lung Function of Lung Health Study Participants after 11 Years. Am J Respir Crit Care Med 2002; 166: 675-9.
18. Warnier MJ, van Riet EES, Rutten FH, et al. Smoking cessation strategies in patients with COPD. Eur Respir J 2013; 41: 727-34.
19. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204.
20. Sehatzadeh S. Influenza and Pneumococcal Vaccinations for Patients With Chronic Obstructive Pulmonary Disease (COPD). Ont Health Technol Assess Ser 2012; 12: 1-64.
21. Spruit MA, Singh SJ, Garvey C, et al. An Official American Thoracic Society/European Respiratory Society Statement: Key Concepts and Advances in Pulmonary Rehabilitation. Am J Respir Crit Care Med 2013; 188: e13-e64.
22. Spruit MA, Clini EM. Towards health benefits in chronic respiratory diseases: pulmonary rehabilitation. Eur Respir Rev 2013; 22: 202-4.
23. Goldstein RS, Hill K, Brooks D, Dolmage TE. Pulmonary rehabilitation: A review of the recent literature. Chest 2012; 142: 738-49.
24. Gloeckl R, Marinov B, Pitta F. Practical recommendations for exercise training in patients with COPD. Eur Respir Rev 2013; 22: 178-86.
25. Hill K, Vogiatzis I, Burtin C. The importance of components of pulmonary rehabilitation, other than exercise training, in COPD. Eur Respir Rev 2013; 22: 405-13.
26. Chronic obstructive pulmonary disease: Management of chronic obstructive pulmonary disease in adults in primary and secondary care (partial update). Available from: http://egap. evidence. nhs. uk/chronic-obstructive-pulmonary-disease-cg101. Accessed December 2013.
27. Hanania NA, R. Celli B, Donohue JF, Martin UJ. Bronchodilator reversibility in COPD. Chest 2011; 140: 1055-63.
28. Cook D, Guyatt G, Wong E, et al. Regular Versus As-Needed Short-Acting Inhaled β-Agonist Therapy for Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2001; 163: 85-90.
29. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. an 85-day multicenter trial. Combivent inhalation aerosol study group. Chest 1994; 105: 1411-9.
30. Cazzola M, Page CP, Calzetta L, Matera MG. Pharmacology and Therapeutics of Bronchodilators. Pharmacol Rev 2012; 64: 450-504.
31. Stockley RA, Chopra N, Rice L. Addition of salmeterol to existing treatment in patients with COPD: a 12 month study. Thorax 2006; 61: 122-8.
32. Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease. N Engl J Med 2007; 356: 775-89.
33. Ejiofor S, Turner AM. Pharmacotherapies for COPD. Clin Med Insights Circ Respir Pulm Med 2013; 7: 17-34.
34. Cazzola M, Matera MG, Santangelo G, et al. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med 1995; 89: 357-62.
35. Cazzola M, Bardaro F, Stirpe E. The role of indacaterol for chronic obstructive pulmonary disease (COPD). J Thorac Dis 2013; 5: 559-66.
36. Donohue JF, Fogarty C, Lötvall J, et al. Once-Daily Bronchodilators for Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2010; 182: 155-62.
37. Chapman KR, Rennard SI, Dogra A, et al. Long-term safety and efficacy of indacaterol, a long-acting β2-agonist, in subjects with copd: A randomized, placebo-controlled study. Chest 2011; 140: 68-75.
38. McKeage K. Indacaterol a review of its use as maintenance therapy in patients with chronic obstructive pulmonary disease. Drugs 2012; 72: 543-63.
39. Wang J, Nie B, Xiong W, Xu Y. Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis. J Clin Pharm Ther 2012; 37: 204-11.
40. Tashkin DP, Celli B, Senn S, et al. A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease. N Engl J Med 2008; 359: 1543-54.
41. Mathioudakis AG, Kanavidis P, Chatzimavridou-Grigoriadou V, et al. Tiotropium HandiHaler Improves the Survival of Patients with COPD: A Systematic Review and Meta-Analysis. J Aerosol Med Pulm Drug Deliv 2014; 27: 43-50.
42. Kerwin EM, D'Urzo AD, Gelb AF, et al. Efficacy and Safety of a 12-week Treatment with Twice-daily Aclidinium Bromide in COPD Patients (ACCORD COPD I). COPD 2012; 9: 90-101.
43. Jones PW, Singh D, Bateman ED, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J 2012; 40: 830-6.
44. D'Urzo A, Ferguson G, van Noord J, et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res 2011; 12: 156.
45. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD. N Engl J Med 2011; 364: 1093-103.
46. Chong J, Karner C, Poole P. Tiotropium versus long-acting betaagonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 9.
47. Rodrigo GJ, Plaza V, Castro-Rodríguez JA. Comparison of three combined pharmacologic approaches with tiotropium monotherapy in stable moderate to severe COPD: A systematic review. Pulm Pharmacol Ther 2012; 25: 40-7.
48. van der Molen T, Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim Care Respir J 2012; 21: 101-8.
49. Hughes AD, McNamara A, Steinfeld T. Chapter 3-Multivalent Dual Pharmacology Muscarinic Antagonist and β2 Agonist (MABA) Molecules for the Treatment of COPD. In: Progress in Medicinal Chemistry. Lawton G, Witty DR (Editors). Elsevier; 2012. pp. 71-95.
50. Wielders PLML, Ludwig-Sengpiel A, Locantore N, et al. A new class of bronchodilator improves lung function in COPD: a trial with GSK961081. Eur Respir J 2013; 42: 972-81.
51. Ram F, Jones P, Jardim J, et al. Oral theophylline for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 1996.
52. Page CP. Doxofylline: A "Novofylline". Pulm Pharmacol Ther 2010; 23: 231-4.
53. Cazzola M, Rogliani P, Novelli L, Matera MG. Inhaled corticosteroids for chronic obstructive pulmonary disease. Expert Opin Pharmacother 2013; 14: 2489-99.
54. Agarwal R, Aggarwal AN, Gupta D, Jindal SK. Inhaled corticosteroids vs placebo for preventing copd exacerbations: A systematic review and metaregression of randomized controlled trials. Chest 2010; 137: 318-25.
55. Yang I, Clarke M, Sim E, Fong K. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Systematic Reviews 2012; 7.
56. Soriano JB, Sin DD, Zhang X, et al. A pooled analysis of fev1 decline in copd patients randomized to inhaled corticosteroids or placebo. CHEST Journal 2007; 131: 682-9.
57. Drummond M, Dasenbrook EC, Pitz MW et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: A systematic review and meta-analysis. JAMA 2008; 300: 2407-16.
58. Mathioudakis AG, Amanetopoulou SG, Gialmanidis IP et al. Impact of long-term treatment with low-dose inhaled corticosteroids on the bone mineral density of chronic obstructive pulmonary disease patients: Aggravating or beneficial? Respirology 2013; 18: 147-53.
59. Zervas E, Samitas K, Gaga M, et al. Inhaled Corticosteroids in COPD: Pros and Cons. Curr Drug Targets 2013; 14: 192-224.
60. Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease. Eur Respir J 2003; 22: 912-9.
61. Rodrigo GJ, Castro-Rodriguez JA, Plaza V. Safety and efficacy of combined long-acting β-agonists and inhaled corticosteroids vs long-acting β-agonists monotherapy for stable copd: A systematic review. CHEST 2009; 136: 1029-38.
62. Walters J, Walters H, Wood-Baker R. Oral corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Sys Rev 1996.
63. Poole P, Black P, Cates C. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Sys Rev 2012; 8.
64. Albert RK, Connett J, Bailey WC, et al. Azithromycin for Prevention of Exacerbations of COPD. N Engl J Med 2011; 365: 689-98.
65. Siafakas NM. Preventing Exacerbations of COPD-Advice from Hippocrates. N Engl J Med 2011; 365: 753-4.
66. Stoller JK, Panos RJ, Krachman S, et al. Oxygen therapy for patients with copd: Current evidence and the long-term oxygen treatment trial. Chest 2010; 138: 179-87.
67. O'Reilly P, Bailey W. Long-term continuous oxygen treatment in chronic obstructive pulmonary disease: proper use, benefits and unresolved issues. Curr Opin Pulm Med 2007; 13: 120-4.
68. Papi A, Romagnoli M, Baraldo S, et al. Partial Reversibility of Airflow Limitation and Increased Exhaled NO and Sputum Eosinophilia in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2000; 162: 1773-7.
69. Siva R, Green RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J 2007; 29: 906-13.
70. Miravitlles M, Soler-Cataluña JJ, Calle M, Soriano JB. Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice. Eur Respir J 2013; 41: 1252-6.
71. Corlateanu A, Pripa V, Montanari G, Botnaru V. Overlap Syndrome in Respiratory Medicine: Asthma and COPD. J CardioThoracic Med 2014; 2: 109-12.
72. Amir A. Zeki MS, Andrew Chan, Timothy E. Albertson, and Samuel Louie. The Asthma-COPD Overlap Syndrome: A Common Clinical Problem in the Elderly. J Allergy (Cairo) 2011; 2011: 861926.